Key result
Novel biomarkers such as ST2 and galectin-3 require testing during exercise to determine their potential role in diagnosing early heart failure with preserved ejection fraction.
Highlights the potential of testing novel biomarkers (e.g., ST2, GDF-15, galectin-3) during exercise to improve the diagnosis of early HFpEF.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for exercise testing of ST2 and galectin-3 in early HFpEF; prospective validation required before clinical consideration.
Early heart failure with preserved ejection fraction (HFpEF) is a frequent disease, but its diagnosis is difficult and relies mostly on the evidence of left ventricular filling pressure (LVFP) elevation during exercise. Several reports have suggested that natriuretic peptides plasma levels reflect exercise-induced increase in LVFP, but they still have significant limitations. In this context, any new laboratory biomarker that can accurately reflect LVFP elevation during exercise is desirable. Recently, cardiotrophin-1, soluble endoglin, ST2, growth differentiation factor 15, galectin-3, and other new laboratory markers associated with LVFP have emerged. However, the current data on the relationship of these biomarkers and diastolic dysfunction are limited to resting conditions. Therefore, their secretion deserves to be tested under the exercise to determine their potential role in making a diagnosis of early HFpEF.
No takes yet. Share an insight, caveat, or question.
Meluzı́n et al. (2015) conducted a review in Early heart failure with preserved ejection fraction (HFpEF). Novel biomarkers (cardiotrophin-1, soluble endoglin, ST2, GDF-15, galectin-3) was evaluated. Novel biomarkers such as ST2 and galectin-3 require testing during exercise to determine their potential role in diagnosing early heart failure with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: